FDA issues first AI-focused cGMP warning letter, flagging oversight gaps for manufacturers

The FDA has issued its first warning letter that explicitly addresses the use of artificial intelligence in pharmaceutical manufacturing, targeting Purolea Cosmetics Lab.

The letter cites AI‑generated documentation failures and a lack of quality‑unit oversight, prompting the company to stop drug production.

Inspectors also identified broader cGMP deficiencies, including inadequate process validation, reinforcing that existing regulations apply regardless of AI involvement.

Regulatory experts say the action is a traditional cGMP enforcement, not a new AI‑specific framework, and stress that human supervision and quality controls remain essential.